Stemline Therapeutics Reports Fourth Quarter 2014 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/11/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. TMUS
7. SPY
8. CVS
9. UNH
10. ZETA

Go back to Stemline Therapeutics Reports Fourth Quarter 2014 Financial Results

Stemline Therapeutics (STML) PT Trimmed at Wedbush; Shares Remain Undervalued

March 17, 2015 12:23 PM EDT

Wedbush analyst David Nierengarten reiterated an Outperform rating on Stemline Therapeutics (NASDAQ: STML) but trimmed his price target to $35.00 (from $49.00) after the company reported a smaller-than-expected Q4 loss. The target cut comes as they push out their launch timeline. However, they still view the stock... More

Stemline Therapeutics (STML) Misses Q4 EPS by 2c

March 16, 2015 7:12 AM EDT

Stemline Therapeutics (NASDAQ: STML) reported Q4 EPS of ($0.53), $0.02 worse than the analyst estimate of ($0.51).

Stemline ended the fourth quarter of 2014 with $58.6 million in cash, cash equivalents and investments, as compared to $65.0 million as of September 30, 2014. In January 2015, the Company completed an equity offering... More